It has also been shown that everolimus is equally active in PIK3CA wild-type and mutant types of breast cancer, which suggests that other pathways (e.g., MAPK signaling) could activate mTOR complexes even in the absence of PI3K overactivation [114]. Here, MTOR is linked to breast cancer.